-
I.
Sougklakos,
I.
Boukovinas,
S.
Xynogalos,
S.
Kakolyris,
N.
Ziras,
M.
Vaslamatzis,
A.
Athanasiadis,
A.
Ardavanis,
N.
Androulakis,
A.
Christopoulou,
P.
Makrantonakis,
I.
Bompolaki,
C.
Christofyllakis,
N.
Kentepozidis,
Christos
Emmanouilides,
C.
Kouroussis,
E.
Prinarakis,
A.
Kalisperi,
D.
Mavroudis,
V.
Georgoulias
(2019)
Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.
Journal of Clinical Oncology
-
(
CommitteeCCC.
Chinese guidelines on the management of colorectal cancer (2019.V1). 2019.)
CommitteeCCC.
Chinese guidelines on the management of colorectal cancer (2019.V1). 2019.
CommitteeCCC.
Chinese guidelines on the management of colorectal cancer (2019.V1). 2019.,
CommitteeCCC.
Chinese guidelines on the management of colorectal cancer (2019.V1). 2019.
-
A.
Sobrero,
S.
Lonardi,
G.
Rosati,
M.
Bartolomeo,
M.
Ronzoni,
N.
Pella,
M.
Scartozzi,
M.
Banzi,
M.
Zampino,
F.
Pasini,
P.
Marchetti,
M.
Cantore,
A.
Zaniboni,
L.
Rimassa,
L.
Ciuffreda,
D.
Ferrari,
V.
Zagonel,
E.
Maiello,
S.
Barni,
E.
Rulli,
R.
Labianca
(2018)
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 15
-
(
IvesonTJKerrRSSaundersMP, et al
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol
2018; 19: 562–578.29611518)
IvesonTJKerrRSSaundersMP, et al
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol
2018; 19: 562–578.29611518
IvesonTJKerrRSSaundersMP, et al
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol
2018; 19: 562–578.29611518,
IvesonTJKerrRSSaundersMP, et al
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol
2018; 19: 562–578.29611518
-
(
TierneyJFStewartLAGhersiD, et al
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials
2007; 8: 16.17555582)
TierneyJFStewartLAGhersiD, et al
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials
2007; 8: 16.17555582
TierneyJFStewartLAGhersiD, et al
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials
2007; 8: 16.17555582,
TierneyJFStewartLAGhersiD, et al
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials
2007; 8: 16.17555582
-
S.
Palmer,
D.
Mavridis,
E.
Navarese,
J.
Craig,
M.
Tonelli,
G.
Salanti,
N.
Wiebe,
M.
Ruospo,
D.
Wheeler,
G.
Strippoli
(2015)
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis
The Lancet, 385
-
(
ChengJCaiMShuaiX, et al
Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol
2019; 11: 1758835919838963.31044021)
ChengJCaiMShuaiX, et al
Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol
2019; 11: 1758835919838963.31044021
ChengJCaiMShuaiX, et al
Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol
2019; 11: 1758835919838963.31044021,
ChengJCaiMShuaiX, et al
Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol
2019; 11: 1758835919838963.31044021
-
(
National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Colon cancer, version 2. 2019, https://www.nccn.org (2019, accessed 5
15 2019).)
National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Colon cancer, version 2. 2019, https://www.nccn.org (2019, accessed 5
15 2019).
National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Colon cancer, version 2. 2019, https://www.nccn.org (2019, accessed 5
15 2019).,
National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Colon cancer, version 2. 2019, https://www.nccn.org (2019, accessed 5
15 2019).
-
(
HashiguchiYMuroKSaitoY, et al
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. Epub ahead of print 15
6
2019 DOI: 10.1007/s10147-019-01485-z.)
HashiguchiYMuroKSaitoY, et al
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. Epub ahead of print 15
6
2019 DOI: 10.1007/s10147-019-01485-z.
HashiguchiYMuroKSaitoY, et al
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. Epub ahead of print 15
6
2019 DOI: 10.1007/s10147-019-01485-z.,
HashiguchiYMuroKSaitoY, et al
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. Epub ahead of print 15
6
2019 DOI: 10.1007/s10147-019-01485-z.
-
R.
Siegel,
K.
Miller,
A.
Jemal
(2019)
Cancer statistics, 2019
CA: A Cancer Journal for Clinicians, 69
-
Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial
-
(2019)
Chinese guidelines on the management of colorectal cancer
-
Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project
-
A.
Cipriani,
J.
Higgins,
J.
Geddes,
G.
Salanti
(2013)
Conceptual and Technical Challenges in Network Meta-analysis
Annals of Internal Medicine, 159
-
(
YoshinoTYamanakaTOkiE, et al
Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol. Epub ahead of print 12
9
2019 DOI: 10.1001/jamaoncol.2019.2572.)
YoshinoTYamanakaTOkiE, et al
Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol. Epub ahead of print 12
9
2019 DOI: 10.1001/jamaoncol.2019.2572.
YoshinoTYamanakaTOkiE, et al
Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol. Epub ahead of print 12
9
2019 DOI: 10.1001/jamaoncol.2019.2572.,
YoshinoTYamanakaTOkiE, et al
Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol. Epub ahead of print 12
9
2019 DOI: 10.1001/jamaoncol.2019.2572.
-
(
GrotheyASobreroAFShieldsAF, et al
Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med
2018; 378: 1177–1188.29590544)
GrotheyASobreroAFShieldsAF, et al
Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med
2018; 378: 1177–1188.29590544
GrotheyASobreroAFShieldsAF, et al
Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med
2018; 378: 1177–1188.29590544,
GrotheyASobreroAFShieldsAF, et al
Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med
2018; 378: 1177–1188.29590544
-
T.
Iveson,
R.
Kerr,
M.
Saunders,
J.
Cassidy,
N.
Hollander,
J.
Tabernero,
A.
Haydon,
B.
Glimelius,
A.
Harkin,
K.
Allan,
J.
McQueen,
C.
Scudder,
K.
Boyd,
A.
Briggs,
A.
Waterston,
L.
Medley,
Charles
Wilson,
R.
Ellis,
S.
Essapen,
A.
Dhadda,
M.
Harrison,
S.
Falk,
S.
Raouf,
C.
Rees,
R.
Olesen,
D.
Propper,
J.
Bridgewater,
A.
Azzabi,
D.
Farrugia,
A.
Webb,
D.
Cunningham,
T.
Hickish,
A.
Weaver,
S.
Gollins,
H.
Wasan,
J.
Paul
(2018)
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
The Lancet. Oncology, 19
-
(
SobreroALonardiSRosatiG, et al
FOLFOX or CAPOX in stage II to III colon cancer: efficacy results of the Italian three or six colon adjuvant trial. J Clin Oncol
2018; 36: 1478–1485.29620994)
SobreroALonardiSRosatiG, et al
FOLFOX or CAPOX in stage II to III colon cancer: efficacy results of the Italian three or six colon adjuvant trial. J Clin Oncol
2018; 36: 1478–1485.29620994
SobreroALonardiSRosatiG, et al
FOLFOX or CAPOX in stage II to III colon cancer: efficacy results of the Italian three or six colon adjuvant trial. J Clin Oncol
2018; 36: 1478–1485.29620994,
SobreroALonardiSRosatiG, et al
FOLFOX or CAPOX in stage II to III colon cancer: efficacy results of the Italian three or six colon adjuvant trial. J Clin Oncol
2018; 36: 1478–1485.29620994
-
HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. Ann Oncol. Epub ahead of print
-
Ji
Cheng,
M.
Cai,
X.
Shuai,
Jin-bo
Gao,
Guobin
Wang,
K.
Tao
(2018)
Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta‐analysis of 143 randomized controlled trials
International Journal of Cancer, 142
-
Ji
Cheng,
M.
Cai,
X.
Shuai,
Jin-bo
Gao,
Guobin
Wang,
K.
Tao
(2019)
Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis
Therapeutic Advances in Medical Oncology, 11
-
FP (3M)' did not display non-inferiority against 'FP (6M)'. The 12-month capecitabine monotherapy only exhibited superiority against 6-month oxaliplatin-based chemotherapy in terms of leucopenia
-
N.
Dubrawsky
(1989)
Cancer statistics
CA: A Cancer Journal for Clinicians, 39
-
(
SiegelRLMillerKDJemalA.
Cancer statistics, 2019. CA Cancer J Clin
2019; 69: 7–34.30620402)
SiegelRLMillerKDJemalA.
Cancer statistics, 2019. CA Cancer J Clin
2019; 69: 7–34.30620402
SiegelRLMillerKDJemalA.
Cancer statistics, 2019. CA Cancer J Clin
2019; 69: 7–34.30620402,
SiegelRLMillerKDJemalA.
Cancer statistics, 2019. CA Cancer J Clin
2019; 69: 7–34.30620402
-
A.
Grothey,
A.
Sobrero,
A.
Shields,
T.
Yoshino,
J.
Paul,
J.
Taieb,
J.
Souglakos,
Q.
Shi,
R.
Kerr,
R.
Labianca,
J.
Meyerhardt,
D.
Vernerey,
T.
Yamanaka,
I.
Boukovinas,
J.
Meyers,
L.
Renfro,
D.
Niedzwiecki,
Toshiaki
Watanabe,
V.
Torri,
M.
Saunders,
D.
Sargent,
T.
André,
T.
Iveson
(2018)
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
The New England Journal of Medicine, 378
-
(
AndreTVernereyDMineurL, et al
Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, phase III trial. J Clin Oncol
2018; 36: 1469–1477.29620995)
AndreTVernereyDMineurL, et al
Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, phase III trial. J Clin Oncol
2018; 36: 1469–1477.29620995
AndreTVernereyDMineurL, et al
Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, phase III trial. J Clin Oncol
2018; 36: 1469–1477.29620995,
AndreTVernereyDMineurL, et al
Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, phase III trial. J Clin Oncol
2018; 36: 1469–1477.29620995
-
Ji
Cheng,
M.
Cai,
X.
Shuai,
Jin-bo
Gao,
Guobin
Wang,
K.
Tao
(2019)
Multimodal treatments for resectable gastric cancer: A systematic review and network meta-analysis.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
-
(
CiprianiAHigginsJPGeddesJR, et al
Conceptual and technical challenges in network meta-analysis. Ann Intern Med
2013; 159: 130–137.23856683)
CiprianiAHigginsJPGeddesJR, et al
Conceptual and technical challenges in network meta-analysis. Ann Intern Med
2013; 159: 130–137.23856683
CiprianiAHigginsJPGeddesJR, et al
Conceptual and technical challenges in network meta-analysis. Ann Intern Med
2013; 159: 130–137.23856683,
CiprianiAHigginsJPGeddesJR, et al
Conceptual and technical challenges in network meta-analysis. Ann Intern Med
2013; 159: 130–137.23856683
-
(
PalmerSCMavridisDNavareseE, et al
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet
2015; 385: 2047–2056.26009228)
PalmerSCMavridisDNavareseE, et al
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet
2015; 385: 2047–2056.26009228
PalmerSCMavridisDNavareseE, et al
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet
2015; 385: 2047–2056.26009228,
PalmerSCMavridisDNavareseE, et al
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet
2015; 385: 2047–2056.26009228
-
R.
Labianca,
B.
Nordlinger,
G.
Beretta,
S.
Mosconi,
M.
Mandalà,
A.
Cervantes,
D.
Arnold
(2013)
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 24 Suppl 6
-
(
LabiancaRNordlingerBBerettaGD, et al
Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol
2013; 24(Suppl. 6): vi64–vi72.24078664)
LabiancaRNordlingerBBerettaGD, et al
Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol
2013; 24(Suppl. 6): vi64–vi72.24078664
LabiancaRNordlingerBBerettaGD, et al
Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol
2013; 24(Suppl. 6): vi64–vi72.24078664,
LabiancaRNordlingerBBerettaGD, et al
Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol
2013; 24(Suppl. 6): vi64–vi72.24078664
-
Ji
Cheng,
M.
Cai,
X.
Shuai,
Jin-bo
Gao,
Guobin
Wang,
K.
Tao
(2019)
Systemic therapy for previously treated advanced gastric cancer: A systematic review and network meta-analysis.
Critical reviews in oncology/hematology, 143
-
J.
Tierney,
L.
Stewart,
D.
Ghersi,
S.
Burdett,
M.
Sydes
(2007)
Practical methods for incorporating summary time-to-event data into meta-analysis
Trials, 8
-
Multimodal treatments for resectable gastric cancer: a systematic review and network meta-analysis
-
Y.
Hashiguchi,
K.
Muro,
Yutaka
Saito,
Yoshinori
Ito,
Y.
Ajioka,
T.
Hamaguchi,
K.
Hasegawa,
K.
Hotta,
H.
Ishida,
M.
Ishiguro,
S.
Ishihara,
Y.
Kanemitsu,
Y.
Kinugasa,
K.
Murofushi,
T.
Nakajima,
S.
Oka,
Toshiaki
Tanaka,
H.
Taniguchi,
A.
Tsuji,
K.
Uehara,
H.
Ueno,
T.
Yamanaka,
K.
Yamazaki,
Masahiro
Yoshida,
T.
Yoshino,
M.
Itabashi,
K.
Sakamaki,
K.
Sano,
Y.
Shimada,
Shinji
Tanaka,
H.
Uetake,
S.
Yamaguchi,
Naohiko
Yamaguchi,
H.
Kobayashi,
K.
Matsuda,
K.
Kotake,
K.
Sugihara
(2019)
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
International Journal of Clinical Oncology, 25
-
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
-
(
SouglakosJBoukovinasIKakolyrisS, et al
Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. Ann Oncol. Epub ahead of print 6
2019 DOI: 10.1093/annonc/mdz193.)
SouglakosJBoukovinasIKakolyrisS, et al
Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. Ann Oncol. Epub ahead of print 6
2019 DOI: 10.1093/annonc/mdz193.
SouglakosJBoukovinasIKakolyrisS, et al
Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. Ann Oncol. Epub ahead of print 6
2019 DOI: 10.1093/annonc/mdz193.,
SouglakosJBoukovinasIKakolyrisS, et al
Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. Ann Oncol. Epub ahead of print 6
2019 DOI: 10.1093/annonc/mdz193.
-
National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Colon cancer, version 2
-
T.
André,
D.
Vernerey,
L.
Mineur,
J.
Bennouna,
J.
Desramé,
R.
Faroux,
S.
Fratté,
Marine
Larauze,
S.
Paget‐Bailly,
B.
Chibaudel,
J.
Bez,
J.
Dauba,
C.
Louvet,
C.
Lepère,
O.
Dupuis,
Y.
Bécouarn,
M.
Mabro,
J.
Egreteau,
O.
Bouché,
G.
Deplanque,
M.
Ychou,
M.
Galais,
F.
Ghiringhelli,
L.
Dourthe,
J.
Bachet,
A.
Khalil,
F.
Bonnetain,
A.
Gramont,
J.
Taieb
(2018)
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 15
-
Clinical practice guidelines in oncology
-
T.
Yoshino,
T.
Yamanaka,
E.
Oki,
M.
Kotaka,
D.
Manaka,
T.
Eto,
J.
Hasegawa,
A.
Takagane,
Masato
Nakamura,
Takeshi
Kato,
Y.
Munemoto,
S.
Takeuchi,
H.
Bando,
H.
Taniguchi,
M.
Gamoh,
M.
Shiozawa,
T.
Mizushima,
S.
Saji,
Y.
Maehara,
A.
Ohtsu,
M.
Mori
(2019)
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer
JAMA Oncology, 5